FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208811501> ?p ?o ?g. }

• W3208811501 endingPage "8189" @default.
• W3208811501 startingPage "8179" @default.
• W3208811501 abstract "Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy are recommended for first-line treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). However, not all CDK4/6i trials have reported significant overall survival (OS) benefit, and there have been no head-to-head trials. Two trials have reported OS outcomes in first-line patients: MONALEESA-3 reported significant OS benefit with first- or second-line ribociclib plus fulvestrant (RIB+FUL) versus placebo plus fulvestrant (PBO+FUL), while PALOMA-1 reported no significant OS benefit for palbociclib plus letrozole (PAL+LET) versus LET in first-line postmenopausal patients. Matched-adjusted indirect comparisons (MAICs) are an established method for comparing efficacy of treatments from different trials. We used an MAIC to compare first-line patients from MONALEESA-3 and PALOMA-1.An unanchored MAIC of progression-free survival (PFS) and OS in first-line patients with HR+/HER2- ABC treated with RIB+FUL versus PAL+LET was conducted using individual patient data from MONALEESA-3 and aggregated data from PALOMA-1. To match patients in PALOMA-1, patients in MONALEESA-3 were limited to those with no prior endocrine therapy for ABC and no (neo) adjuvant LET ≤12 months before enrollment. PFS and OS were compared using Kaplan-Meier estimators and Cox regression.A total of 329 and 178 patients from RIB+FUL and PBO+FUL arms, respectively, of MONALEESA-3 were matched to 84 and 81 patients from PAL+LET and LET arms of PALOMA-1. After weighting, OS was significantly longer for RIB+FUL versus PAL+LET (hazard ratio [HR], 0.50; 95% CI, 0.32-0.77; p = 0.0020). PFS favored RIB+FUL versus PAL+LET, although the difference was not statistically significant (HR, 0.77; 95% CI, 0.54-1.10; p = 0.1553).Using MAIC to adjust for trial differences, OS comparisons favored RIB+FUL over PAL+LET as first-line treatment in postmenopausal patients with HR+/HER2- ABC. These exploratory results suggest a significant increase in OS benefit with RIB treatment compared with PAL." @default.
• W3208811501 created "2021-11-08" @default.
• W3208811501 creator A5000220367 @default.
• W3208811501 creator A5001188908 @default.
• W3208811501 creator A5009846821 @default.
• W3208811501 creator A5017728105 @default.
• W3208811501 creator A5018111705 @default.
• W3208811501 creator A5020968880 @default.
• W3208811501 creator A5025974023 @default.
• W3208811501 creator A5041912334 @default.
• W3208811501 creator A5058474941 @default.
• W3208811501 creator A5068059897 @default.
• W3208811501 creator A5088601230 @default.
• W3208811501 date "2021-11-01" @default.
• W3208811501 modified "2023-10-14" @default.
• W3208811501 title "Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer" @default.
• W3208811501 cites W1982967337 @default.
• W3208811501 cites W2005947177 @default.
• W3208811501 cites W2105084636 @default.
• W3208811501 cites W2144790402 @default.
• W3208811501 cites W2160584021 @default.
• W3208811501 cites W2290950904 @default.
• W3208811501 cites W2552099557 @default.
• W3208811501 cites W2558360748 @default.
• W3208811501 cites W2620993107 @default.
• W3208811501 cites W2650689221 @default.
• W3208811501 cites W2763875663 @default.
• W3208811501 cites W2769552107 @default.
• W3208811501 cites W2793826158 @default.
• W3208811501 cites W2804105316 @default.
• W3208811501 cites W2804580221 @default.
• W3208811501 cites W2805575723 @default.
• W3208811501 cites W2898724324 @default.
• W3208811501 cites W2909018550 @default.
• W3208811501 cites W2972049666 @default.
• W3208811501 cites W3031130887 @default.
• W3208811501 cites W3043082495 @default.
• W3208811501 doi "https://doi.org/10.2147/cmar.s325043" @default.
• W3208811501 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8570288" @default.
• W3208811501 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34754238" @default.
• W3208811501 hasPublicationYear "2021" @default.
• W3208811501 type Work @default.
• W3208811501 sameAs 3208811501 @default.
• W3208811501 citedByCount "0" @default.
• W3208811501 crossrefType "journal-article" @default.
• W3208811501 hasAuthorship W3208811501A5000220367 @default.
• W3208811501 hasAuthorship W3208811501A5001188908 @default.
• W3208811501 hasAuthorship W3208811501A5009846821 @default.
• W3208811501 hasAuthorship W3208811501A5017728105 @default.
• W3208811501 hasAuthorship W3208811501A5018111705 @default.
• W3208811501 hasAuthorship W3208811501A5020968880 @default.
• W3208811501 hasAuthorship W3208811501A5025974023 @default.
• W3208811501 hasAuthorship W3208811501A5041912334 @default.
• W3208811501 hasAuthorship W3208811501A5058474941 @default.
• W3208811501 hasAuthorship W3208811501A5068059897 @default.
• W3208811501 hasAuthorship W3208811501A5088601230 @default.
• W3208811501 hasBestOaLocation W32088115011 @default.
• W3208811501 hasConcept C121608353 @default.
• W3208811501 hasConcept C126322002 @default.
• W3208811501 hasConcept C142724271 @default.
• W3208811501 hasConcept C143998085 @default.
• W3208811501 hasConcept C204787440 @default.
• W3208811501 hasConcept C27081682 @default.
• W3208811501 hasConcept C2775930923 @default.
• W3208811501 hasConcept C2777176818 @default.
• W3208811501 hasConcept C2778812593 @default.
• W3208811501 hasConcept C2779744173 @default.
• W3208811501 hasConcept C2780482068 @default.
• W3208811501 hasConcept C2780739268 @default.
• W3208811501 hasConcept C29456083 @default.
• W3208811501 hasConcept C3019894029 @default.
• W3208811501 hasConcept C530470458 @default.
• W3208811501 hasConcept C71924100 @default.
• W3208811501 hasConcept C84606932 @default.
• W3208811501 hasConceptScore W3208811501C121608353 @default.
• W3208811501 hasConceptScore W3208811501C126322002 @default.
• W3208811501 hasConceptScore W3208811501C142724271 @default.
• W3208811501 hasConceptScore W3208811501C143998085 @default.
• W3208811501 hasConceptScore W3208811501C204787440 @default.
• W3208811501 hasConceptScore W3208811501C27081682 @default.
• W3208811501 hasConceptScore W3208811501C2775930923 @default.
• W3208811501 hasConceptScore W3208811501C2777176818 @default.
• W3208811501 hasConceptScore W3208811501C2778812593 @default.
• W3208811501 hasConceptScore W3208811501C2779744173 @default.
• W3208811501 hasConceptScore W3208811501C2780482068 @default.
• W3208811501 hasConceptScore W3208811501C2780739268 @default.
• W3208811501 hasConceptScore W3208811501C29456083 @default.
• W3208811501 hasConceptScore W3208811501C3019894029 @default.
• W3208811501 hasConceptScore W3208811501C530470458 @default.
• W3208811501 hasConceptScore W3208811501C71924100 @default.
• W3208811501 hasConceptScore W3208811501C84606932 @default.
• W3208811501 hasLocation W32088115011 @default.
• W3208811501 hasLocation W32088115012 @default.
• W3208811501 hasLocation W32088115013 @default.
• W3208811501 hasLocation W32088115014 @default.
• W3208811501 hasOpenAccess W3208811501 @default.
• W3208811501 hasPrimaryLocation W32088115011 @default.
• W3208811501 hasRelatedWork W13189666 @default.

• next